Moving forward with capecitabine: A glimpse of the future

Oncologist

Volumn 7, Issue SUPPL. 6, 2002, Pages 29-35

  Biganzoli, Laura ^a   Martin, Miguel ^b   Twelves, Chris ^c  

^a JULES BORDET INSTITUTE   (Belgium)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Anthracyclines; Breast cancer; Capecitabine; Taxanes; Trastuzumab; Vinorelbine

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; NAVELBINE; NEU DIFFERENTIATION FACTOR; PACLITAXEL; TAXANE DERIVATIVE; THYMIDINE PHOSPHORYLASE; TRASTUZUMAB;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; FATIGUE; FEVER; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; METASTASIS; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; PARESTHESIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; STOMATITIS; VOMITING;

EID: 0036913677     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.2002-0029     Document Type: Conference Paper

References (25)

1. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20:2812-2823.
2. Blum JL, Jones SE, Buzdar AU et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-493.
3. Blum JL, Dieras V, Lo Russo PM et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001;92:1759-1768.
4. Fumoleau P, Largillier R, Trillet-Lenoir V et al. Phase II study of capecitabine (Xeloda®) in pts with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes. Breast Cancer Res Treat 2001;69:285a.
5. Reichardt P, von Minckwitz G, Luck HJ et al. Capecitabine: The new standard in metastatic breast cancer failing anthracycline and taxane-containing chemotherapy? Mature results of a large multicenter phase II trial. Eur J Cancer 2001;37(suppl 6):S191a.
6. Talbot DC, Moiseyenko V, Van Belle S et al. Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002;86:1367-1372.
7. Beisecker A, Cook MR, Ashworth J et al. Side effects of adjuvant chemotherapy: Perceptions of node-negative breast cancer patients. Psychooncology 1997;6:85-93.
8. Love RR, Leventhal H, Easterling DV et al. Side effects and emotional distress during cancer chemotherapy. Cancer 1989;63:604-612.
9. O'Shaughnessy JA, Blum J, Moiseyenko V et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12:1247-1254.
10. Sawada N, Ishikawa T, Fukase Y et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013-1019.
11. Villalona-Calero MA, Weiss GR, Burris HA et al. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol 1999;17:1915-1925.
12. Villalona-Calero MA, Blum JL, Jones SE et al. A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients. Ann Oncol 2001;12:605-614.
13. Pérez-Manga G, Batista N, Constenla M et al. Efficacy and safety profile of capecitabine (Xeloda®) in combination with paclitaxel (P) in patients with locally advanced or metastatic breast cancer: Preliminary results of a phase II study. Breast Cancer Treat Res 2000;64:124a.
14. Meza LA, Amin B, Hill T et al. Capecitabine plus paclitaxel as first- or second-line therapy: A multicentre phase II study in metastatic breast cancer. Breast Cancer Res Treat 2001;69:271a.
15. Nolè F, Catania C, Mandalá M et al. Phase I study of vinorelbine (V) and capecitabine (C) in advanced breast cancer (ABC). Breast Cancer Res Treat 2000;64:125a.
16. Welt A, Borquez D, Oberhoff C et al. Phase I study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2001;20:58b.
17. Biganzoli L, Bonnefoi H, Mauriac L et al. Cyclophosphamide (C) - epirubicin (E) - capecitabine (X) combination, CEX; a safe and active regimen in the treatment of locally advanced/inflammatory (LA/I) or large operable (LO) breast cancer (BC). An EORTC-IDBBC study. Eur J Cancer 2001;39(suppl 6):146a.
18. Venturini M, Del Mastro L, Garrone O et al. Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer. Ann Oncol 2002;13:546-552.
19. Rosso R, Del Mastro L, Durando A et al. Capecitabine in association with epirubicin and docetaxel as a first-line treatment in advanced breast cancer. A multicenter phase II study. Breast Cancer Res Treat 2001;69:270a.
20. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648.
21. Smith IE. Efficacy and safety of Herceptin® in women with metastatic breast cancer: Results from pivotal clinical studies. Anticancer Drugs 2001;12(suppl 4):S3-S10.
22. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
23. Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast cancer models. Cancer Chemother Pharmacol 2002;49:211-216.
24. Bangemann N, Kuhle A, Ebert A et al. Capecitabine combined with trastuzumab in the therapy of intensively pretreated HER2-overexpressing metastatic breast cancer (MBC). Ann Oncol 2000;11(suppl 4):143a.
25. Cobleigh MA, Miller KD, Langmuir VK et al. Phase II dose escalation trial of Avastin™ (bevacizumab) in women with previously treated metastatic breast cancer. Breast Cancer Treat Res 2001;69:301a.